COVID-19 candidate vaccine mRNA-1273 III clinical trial: the scale will continue to expand.
-
Last Update: 2020-07-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
!---- Clinical Biotech company Moderna is a pioneer in messenger RNA (mRNA) therapeutics and vaccines, and Moderna today announced an additional $472 million investment in BARDA (Biomedical Advanced Research and Development Agency) to support late-stage clinical development, including the expansion of clinical trials of mRNA vaccine candidate s /mRNA-1273 III for COVID-19BARDA has previously received an investment of up to $483 million to support the clinical development of mRNA-1273, however, the initial Phase III clinical trial involved is relatively smallAfter discussions with the U.SFood and Drug Administration (FDA), Moderna decided to conduct a larger Phase III clinical trialUnder the revised terms of the contract, BARDA will expand support for post-clinical development of mRNA-1273, including A Phase III studies of 30,000 participants in the United States"We are grateful to BARDA for its continued support of the COVID-19 candidate vaccine mRNA-1273," said Moderna CEO St?phane BancelEncouraged by the first phase of data, we believe that mRNA-1273 may help address the COVID-19 pandemic and prevent future outbreaks."
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
